[DOI] [PubMed] [Google Scholar] Moran JA, Dahl EL, et al
If you are not yet a member, you can book a free inquiry call or a 60-minute consultation to talk through your goals
Zakrzewski, R., Borowczyk, K., Luczak, A., Mlynarski, W., and Trelinska, J., Bioanalysis , 2013, vol
Future predictions Likely scenarios: More peptides will get FDA approval: Clinical trials ongoing for many peptides If approved, they shift to prescription-only Continued gray area for research peptides: Unlikely FDA will ban possession More likely to restrict sales/marketing Gray area probably persists Increased quality control: Pressure on research peptide industry to ensure quality Third-party testing becoming standard More telehealth access: Legal prescription access becoming easier Online platforms expanding Staying legal: best practices If using research peptides Buy from reputable sources with third-party testing Don't import large quantities (personal amounts only) Don't resell or distribute (keeps you in personal use category) Understand it's gray area (legal risk is low but not zero) Keep discrete (don't advertise use) Use our peptide calculator to determine personal use amounts
